Intra-Cellular Therapies Inc (NASDAQ: ITCI) on Tuesday, plunged -0.01% from the previous trading day, before settling in for the closing price of $131.25. Within the past 52 weeks, ITCI’s price has moved between $63.30 and $131.36.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 7627.06%. The company achieved an average annual earnings per share of 191.46%. With a float of $98.94 million, this company’s outstanding shares have now reached $106.24 million.
Considering the fact that the conglomerate employs 860 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 91.63%, operating margin of -17.15%, and the pretax margin is -10.9%.
Intra-Cellular Therapies Inc (ITCI) Insider Activity
Observing investor behavior towards Drug Manufacturers – Specialty & Generic industry stocks is more important than anything else. The insider ownership of Intra-Cellular Therapies Inc is 6.94%, while institutional ownership is 83.00%. The most recent insider transaction that took place on Dec 04 ’24, was worth 4,375,659. In this transaction Chairman and CEO of this company sold 51,000 shares at a rate of $85.80, taking the stock ownership to the 1,070,329 shares. Before that another transaction happened on Dec 05 ’24, when Company’s Chairman and CEO sold 51,697 for $84.08, making the entire transaction worth $4,346,842. This insider now owns 1,070,329 shares in total.
Intra-Cellular Therapies Inc (ITCI) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 191.46% per share during the next fiscal year.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Trading Performance Indicators
Intra-Cellular Therapies Inc (ITCI) is currently performing well based on its current performance indicators. A quick ratio of 6.23 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 20.50.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.72, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach 4.25 in one year’s time.
Technical Analysis of Intra-Cellular Therapies Inc (ITCI)
Compared to the last year’s volume of 3.74 million, its volume of 2.33 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 96.38%. Additionally, its Average True Range was 0.74.
During the past 100 days, Intra-Cellular Therapies Inc’s (ITCI) raw stochastic average was set at 99.77%, which indicates a significant increase from 96.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 9.80% in the past 14 days, which was lower than the 57.10% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $119.46, while its 200-day Moving Average is $87.54. Nevertheless, the first resistance level for the watch stands at $131.33 in the near term. At $131.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $131.47. If the price goes on to break the first support level at $131.19, it is likely to go to the next support level at $131.14. Should the price break the second support level, the third support level stands at $131.05.
Intra-Cellular Therapies Inc (NASDAQ: ITCI) Key Stats
Market capitalization of the company is 13.95 billion based on 106,328K outstanding shares. Right now, sales total 680,850 K and income totals -74,680 K. The company made 199,220 K in profit during its latest quarter, and -16,890 K in sales during its previous quarter.
